Abstract：Objective: To study the clinicopathological features and prognoses of collecting duct carcinoma (CDC) of the kidney. Methods: A retrospective study was done in 13 cases of CDC. The demographics, perioperative data, follow-up and prognostic information were collected. Results: Thirteen cases of CDC (0.42%) were identified among 3100 cases of kidney cancer admitted in our institute, including 12 males and one female with mean age of 58 (range, 21-81) years. The main symptoms were hematuria, flank pain and loss of weight. The CT scan showed poor blood supply to the lesion in the kidney. Nephrectomy was performed in 12 cases. The mean maximum diameter of tumor was 6.1 (range, 4.0-8.0) cm. Pathological data showed that lymphatic metastases were found in 6 cases and distant metastases were seen in 2 cases. According to TNM tumor stage, there were three cases of stage Ⅰ, 7 cases of stage Ⅲ and 3 cases of stage Ⅳ. Histologic examination indicated prominent tubular or tubulopapillary structures with sarcomatoid carcinoma in some cases. The mean follow-up period was 26.3 (range, 4.0-62.0) months with one patient lost to follow up. The outcome showed 9 patients died of metastasis or organ failure and 3 patients survived. The median survival time was 10.7 months and one-year disease specific survival was 41.6%. Conclusions: CDC of the kidney is a rare histological type of renal cell carcinoma. The pathological examination is the golden standard for the diagnosis and treatments of CDC including the surgical operation, chemotherapy and the targeted therapy. Because of the high degree of malignancy and poor prognosis of CDC, the early diagnosis and comprehensive therapy can benefit the patients.
[1]Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med, 2005,353(23):2477-2490.
[2]Wein AJ, Kavaussi LR, Novick AC, et al. Campbell-Wash Urology. 10th ed. Philadelphia: Elsevier, 2012:1413-1474.
[3]孔祥田, 曾荔, 宓培, 等. 肾集合管癌10例分析. 中华肿瘤杂志, 2001,23(2):162-164.
[4]王艳青, 黄吉炜, 潘家骅,等. 12例肾集合管癌临床病理分析. 临床泌尿外科杂志, 2014,29(10):867-870.
[5]Zhu Q, Wu J, Wang Z, et al. The MSCT and MRI findings of collecting duct carcinoma. Clin Radiol, 2013,68(10):1002-1007.
[6]梁晓超, 王伯胤, 赵振华, 等. 肾癌亚型的CT诊断. 医学研究杂志, 2013,42(5):179-183.
[7]Carter MD, Tha S, McLoughlin MG, et al. Collecting duct carcinoma of the kidney: a case report and review of the literature. J Urol, 1992,147(4):1096-1098.
[8]肖立, 陆孝禹, 朱雄增, 等. 肾集合管癌的临床病理分析. 临床与实验病理学杂志, 2008,24(2):195-198.
[9]Kobayashi N, Matsuzaki O, Shirai S, et al. Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis. Hum Pathol, 2008,39(9):1350-1359.
[10]Oosterwijk E, Rathmell WK, Junker K, et al. Basic research in kidney cancer. Eur Urol, 2011,60(4):622-633.
[11]Procopio G, Testa I, Iacovelli R, et al. Treatment of collecting duct carcinoma: current status and future perspectives. Anticancer Res, 2014,34(2):1027-1030.
[12]Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. J Urol, 2007,177(5):1698-1702.
[13]Kwon KA, Oh SY, Kim HY, et al. Clinical features and treatment of collecting duct carcinoma of the kidney from the Korean cancer study group genitourinary and gynecology cancer committee. Cancer Res Treat, 2014,46(2):141-147.
[14]Tokuda N, Naito S, Matsuzaki O, et al. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol, 2006,176(1):40-43.
[15]May M, Ficarra V, Shariat SF, et al. Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model. J Urol, 2013,190(2):458-463.
